西尼地平治疗轻、中度原发性高血压病人的疗效和安全性

目的 :观察西尼地平治疗轻、中度原发性高血压病人的降压疗效和安全性。方法 :采用随机、双盲、平行对照试验设计。经过 2wk安慰剂洗脱后 ,筛选轻、中度高血压病病人 4 8例。分为A组 2 4例 ,给西尼地平 5mg加苯磺酸氨氯地平模拟片 ,po ,qd ;B组 2 4例 ,为苯磺酸氨氯地平 5mg加西尼地平模拟片 ,po ,qd。 4wk末如达目标血压 (坐位舒张压≤ 12kPa) ,继续服用至 8wk末 ,否则剂量加倍服用至 8wk末。结果 :2组总有效率分别为 75 %和 83% ,2组收缩压降低幅度分别为 (0 .2 6±s 0 .16 )kPa和 (0 .31± 0 .16 )kPa ,舒张压降低幅度分别为 (0 .2 1± 0 .11)kPa和 (0 .2 4± 0 .0 8)kPa(均P <0 .0 1)。不良反应 2组无显著差异。结论 :西尼地平治疗对轻、中度原发性高血压病人有效、安全

Efficacy and safety of cilnildipine in treating mild to moderate essential hypertension

AIM: To observe the efficacy and safety of cilnidipine in treating mild to moderate essential hypertension. METHODS: A randomized, double-blind placebo-controlled clinical study was carried out. Forty-eight patients of sitting diastolic pressure at 12.7-14.7 kPa and sitting systolic pressure <23.9 kPa, were divided into trial group and control group randomly. The trial groups patients received cilnidipine 5 mg, po, qd for 4wk or amlodiping besylate 5 mg, po, qd for 4wk. If sitting diastolic pressure ≥12.0 kPa appeared at 4 wk,cinildipine or amlodipine besylate was increased to dosages of 10 mg, po,qd for 4 wk. The total course of treatment lasted for 8 wk. RESULTS: At the end of 8 wk, the total effective rate of cilnidipine was 75 % and that of amlodipine besylate was 83 %. Cilnidipine and amlodipine besylate significantly reduced both systolic and diastolic pressures, including systolic pressure were reduced (0.26±s 0.16) kPa, vs (0.31±(0.16)) kPa respectively, and diastolic pressure were reduced ((0.21±0.11)) kPa vs (0.24±0.08) kPa, respectively. CONCLUSION: Cilnidipine possesses the same efficacy and safety as amlodipine besylate in treating mild to moderate essential hypertension with satisfactory tolerance.